
    
      This is a Phase 2, open-label, multicenter, 28 week extension study to evaluate the long-term
      safety and tolerability of ABT-126 in subjects who complete dosing through Week 24 of Study
      M11-793. Up to 420 subjects may participate at approximately 40 sites in seven countries.
    
  